Filing Flows › Viatris (VTRS) › Takeover & LBO
Is Viatris (VTRS) a takeover target?
A leveraged buyout does not work for Viatris on its latest figures: its EBITDA margin is only 0.9% ($135M on revenue of $14.3B), too thin to carry buyout debt. Historically 4.0% of companies with its figures were bought within a year (0.8× the average). Latest signal (2026-11-05): Agreed sale to Pacira BioSciences, Inc. at $36.5 cash a share · pending.
Why a leveraged buyout does not fit
Viatris kept 0.9% of its revenue as EBITDA over the last 12 months ($135M on $14.3B). A margin that thin cannot carry the debt a leveraged buyout needs — a small dip in sales would leave nothing for interest — so the model gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Viatris would cost about $25.61 a share, $29.8B for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 22% | $23.14 | $27.0B |
| Median | 35% | $25.61 | $29.8B |
| High end (a quarter paid more) | 45% | $27.51 | $32.0B |
The odds, from history
Historically 4.0% of companies with its figures were bought within a year (0.8× the average). Its figures put it in decile 4 of 10 (10 = the most likely to be bought). The odds come from a model of every merger proxy, tender-offer response and going-private statement filed on EDGAR since 2011, set against each company's size, margins, debt, cash flow and growth the year before.
Rumors and deal signals
- 2026-11-05 · deal · Agreed sale to Pacira BioSciences, Inc. at $36.5 cash a share · pending
Viatris' latest quarter
Viatris, Q3 2026: revenue $3.7B (-0.3% year over year), operating margin 7.0%, net loss $325M, operating cash flow $899M. The chart follows the revenue to costs, profit and cash.
Questions
Is Viatris being acquired?
The latest signal on file is from 2026-11-05: Agreed sale to Pacira BioSciences, Inc. at $36.5 cash a share · pending. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Viatris?
A leveraged buyout does not work for Viatris on its latest figures: its EBITDA margin is only 0.9% ($135M on revenue of $14.3B), too thin to carry buyout debt. A margin that thin leaves almost nothing to pay interest with, so buyout debt does not fit.
What would a takeover of Viatris cost?
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Viatris would cost about $25.61 a share, $29.8B for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.